Matrix metalloproteinases: discrete elevations in essential hypertension and hypertensive end-stage renal disease. - Wikidata - wikimedia - TriplyDB

Matrix metalloproteinases: discrete elevations in essential hypertension and hypertensive end-stage renal disease.

Matrix metalloproteinases: discrete elevations in essential hypertension and hypertensive end-stage renal disease.

http://www.wikidata.org/entity/Q33872836

about

Matrix Metalloproteinases in Non-Neoplastic Disorders.The Discovery of Novel Genomic, Transcriptomic, and Proteomic Biomarkers in Cardiovascular and Peripheral Vascular Disease: The State of the Art Matrix Metalloproteinases and Subclinical Atherosclerosis in Chronic Kidney Disease: A Systematic Review Imbalanced matrix metalloproteinases in cardiovascular complications of end-stage kidney disease: a potential pharmacological target Matrix Metalloproteinase Inhibition Mitigates Renovascular Remodeling in Salt-Sensitive Hypertension.Novel 19F activatable probe for the detection of matrix metalloprotease-2 activity by MRI/MRS.25-hydroxyvitamin D concentration is inversely associated with serum MMP-9 in a cross-sectional study of African American ESRD patients.Receptor cleavage reduces the fluid shear response in neutrophils of the spontaneously hypertensive rat Is there any genetic predisposition of MMP-9 gene C1562T and MTHFR gene C677T polymorphisms with essential hypertension?Angiotensin-II induced hypertension and renovascular remodelling in tissue inhibitor of metalloproteinase 2 knockout mice.Inward remodeling of resistance arteries requires reactive oxygen species-dependent activation of matrix metalloproteinases.Circulating markers of vascular injury and angiogenesis in antineutrophil cytoplasmic antibody-associated vasculitis.A reduced graphene oxide-based fluorescence resonance energy transfer sensor for highly sensitive detection of matrix metalloproteinase 2.Receptor cleavage and P-selectin-dependent reduction of leukocyte adhesion in the spontaneously hypertensive rat.Emergence of a metalloproteinase / phospholipase A2 axis of systemic inflammation.Feature selection and classification of urinary mRNA microarray data by iterative random forest to diagnose renal fibrosis: a two-stage study.Influence of elastin-derived peptides on metalloprotease production in endothelial cells.MMP-2 and sTNF-R1 Variability in Patients with Essential Hypertension: 1-Year Follow-Up Study.Proof of Concept: Matrix metalloproteinase inhibitor decreases inflammation and improves muscle insulin sensitivity in people with type 2 diabetes Roles of Caveolin-1 in Angiotensin II-Induced Hypertrophy and Inward Remodeling of Cerebral Pial Arterioles.Effect of resistance training on biomarkers of vascular function and oxidative stress in young African-American and Caucasian men.Serum Concentrations of Endothelin-1 and Matrix Metalloproteinases-2, -9 in Pre-Hypertensive and Hypertensive Patients with Type 2 Diabetes Proteolytic receptor cleavage in the pathogenesis of blood rheology and co-morbidities in metabolic syndrome. Early forms of autodigestion.Genetic and Adverse Health Outcome Associations with Treatment Resistant Hypertension in GenHAT.Matrix Metalloproteinase (MMP)-9 Levels in Children on Hemodialysis: Association with MMP-9 C-1562T Gene Polymorphism and Vitamin D Levels.Personalized Proteomics: The Future of Precision Medicine.An emerging role of degrading proteinases in hypertension and the metabolic syndrome: autodigestion and receptor cleavage.Matrix metalloproteinases and small artery remodeling.Insights into the activity, differential expression, mutual regulation, and functions of matrix metalloproteinases and a disintegrin and metalloproteinases in hypertension and cardiac disease.Matrix metalloproteinases contribute to kidney fibrosis in chronic kidney diseases.THE AUTODIGESTION HYPOTHESIS AND RECEPTOR CLEAVAGE IN DIABETES AND HYPERTENSION.Extracellular overhydration linked with endothelial dysfunction in the context of inflammation in haemodialysis dependent chronic kidney disease Serum protein pattern associated with organ damage and lupus nephritis in systemic lupus erythematosus revealed by PEA immunoassay Vascular receptors as new substrates for matrix metalloproteinases in hypertension and other inflammatory states.Matrix metalloproteinase (MMP)-2 genetic variants modify the circulating MMP-2 levels in end-stage kidney disease.

P2860

Q26741827-4194F79B-8817-48E2-8DA8-9D77B0381E8F Q26746121-42FEA522-01F0-4C0A-9B9D-0CD4542D0BE9 Q26752715-48DE67A6-4B6C-4F50-BB78-2B6AA2DC98FF Q26864722-2B1CDCF7-CAAD-4A44-974C-6AB55AE02AAF Q30446389-2FC16888-8CB1-4DCE-B667-0A6376E99BC4 Q30856771-76E475E4-1514-478B-AFE1-580B94DB875F Q33907260-39BB35C6-99CC-4912-96F5-328D385F70F5 Q34426368-684C8491-B3B6-4042-B716-6A47D876C924 Q34962185-68964575-F0E5-4578-ABEE-EDDC54869D86 Q35001863-21CAD445-A976-4D0C-BB4E-D107135BE05D Q35056901-0FE230C2-C3F9-4E75-A28F-FE77E9C39C6C Q35583154-18BBC1FB-D603-4176-8907-79A58AF84602 Q36008261-078CCAB0-A692-4322-9A7A-52FA4C87ECCD Q36056004-8D161CE9-2514-4122-BD62-F7131B424EDD Q36176901-09C63842-CF63-4B5A-9969-EC8AC6D97BA5 Q36237627-2D50109C-EFDF-4E6E-BDCC-7306F77791E8 Q36244291-852E26AC-0172-4861-A59F-164E3369AB4A Q36253578-5A7A9647-7204-4B06-8BFE-583A510291F2 Q36427429-C818631B-D769-422D-99E1-81871E15D2C6 Q36576677-408F2B6E-E20D-430A-A221-563F30F77910 Q36632008-F6C35AA0-81AD-47E0-81F6-FCCBC23B74B8 Q37209809-4B33E839-4335-451B-9C54-27B8C6D0A62F Q37228621-149C8985-A600-441A-9E04-B28430B90313 Q37322723-A8282C6B-9524-4DDD-8FDE-9CAF659E2B1C Q37366411-08BA7168-21F5-4F70-8C24-7DEA9709311B Q37426540-4016E21C-C414-450F-8DEF-A5C3EC6E979B Q37955866-F8AF6619-3EC7-43D3-AFB7-FC6C69C48F82 Q37962503-3D500D70-9F62-42E8-9ADE-26942138067E Q38061567-862ED6C1-49FB-4308-B9D2-8AEC81DEF260 Q38164338-3C9E0501-87C5-460C-8A49-C0A07F51F1C1 Q39012642-8AAA85E5-0EBD-415F-A283-A54D52039969 Q41501534-12D383D1-8D35-45C7-B12F-EC9238F6A6EE Q42281246-1DD775A2-DF24-433C-8218-8EF0352B4E84 Q42733133-895495D2-6796-4B89-859C-95C010C34B17 Q54030546-01DCBFDC-A46D-4299-9265-BC2FD0B60FAD

P2860

Matrix metalloproteinases: discrete elevations in essential hypertension and hypertensive end-stage renal disease.

http://www.wikidata.org/entity/Q33872836

description

2009 nî lūn-bûn

@nan

2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Matrix metalloproteinases: dis ...... nsive end-stage renal disease.

@ast

Matrix metalloproteinases: dis ...... nsive end-stage renal disease.

@en

type

label

Matrix metalloproteinases: dis ...... nsive end-stage renal disease.

@ast

Matrix metalloproteinases: dis ...... nsive end-stage renal disease.

@en

prefLabel

Matrix metalloproteinases: dis ...... nsive end-stage renal disease.

@ast

Matrix metalloproteinases: dis ...... nsive end-stage renal disease.

@en

P1433

Q33872836-C4CF387F-2E2E-47FE-B752-17CD96612B66

P1476

Q33872836-744C8F35-9FD7-482E-9F23-6E3094D75D3D

P2093

Q33872836-22F722DF-5894-47D6-94E3-2CD1F2DEFAA4

Q33872836-24F60756-5B8A-4310-84D1-399B874B523A

Q33872836-63EF6C14-FB6F-48DD-A776-F42823F5126B

Q33872836-C95D9882-E9AA-459A-B63D-05ABEC6D3D45

Q33872836-CC8FE2A5-D2A6-4903-8D5E-50DE96925907

Q33872836-FED96735-A236-48F0-84D1-DDFB1707A965

Q33872836-FF433C12-395B-4A94-AD10-F9CCFAD6B53A

P2860

Q33872836-0C231394-D752-45F7-8CE8-84941A1573F2

Q33872836-0EB49539-5E94-43DD-8CEB-B52B1C528EDA

Q33872836-21965B38-7127-41ED-B87A-CEE6BA4906D1

Q33872836-450ACB9F-C071-41BB-ACA0-FC0165F1D122

Q33872836-4FB847EB-584A-45FA-8420-61BBC3CB0DB7

Q33872836-68590CE6-3C82-4D68-B67F-30506BD58989

Q33872836-8C62424A-A212-41A6-BB5D-9D6B92AEF804

Q33872836-98C58208-8C49-4E6C-9EDA-F0619DAD274A

Q33872836-9B1DF17F-1A82-4C6E-B165-11F33873B8C4

Q33872836-9C674EAA-455A-45DD-8295-2A230FB92D2D

P304

Q33872836-F56DA8C7-01FD-4282-AA4C-1FAFB4BB89EA

P31

Q33872836-B3D0B6B1-1E7C-4B4F-8DFA-A06D896DB8F4

P356

Q33872836-464AFCE4-D7DC-4AB2-8E2A-0F24083A282C

P433

Q33872836-2B442BC2-697D-449A-A168-3DA64C52A166

P478

Q33872836-47C85FC2-30F2-4909-8DD9-9A949A4E6A76

P577

Q33872836-E6E817A3-7716-44FF-932D-9BCE8614B957

P5875

Q33872836-00B88299-F8C8-4925-AD94-63188A14D66A

P698

Q33872836-D42669BB-EBEF-44D1-94B9-0F8FD7C5BEE5

P932

Q33872836-EA275FEA-60B3-4EAE-9D02-6FA8686B0424

P356

10641960802668730

P1433

Clinical and Experimental Hypertension

P1476

Matrix metalloproteinases: dis ...... nsive end-stage renal disease.

@en

P2093

Brenda Thomas

http://www.w3.org/2001/XMLSchema#string

Daniel T O'Connor

http://www.w3.org/2001/XMLSchema#string

Fangwen Rao

http://www.w3.org/2001/XMLSchema#string

Geert W Schmid-Schönbein

http://www.w3.org/2001/XMLSchema#string

Michael G Ziegler

http://www.w3.org/2001/XMLSchema#string

Ryan S Friese

http://www.w3.org/2001/XMLSchema#string

Srikrishna Khandrika

http://www.w3.org/2001/XMLSchema#string

P2860

Aspirin inhibits matrix metalloproteinase-2 activity, increases E-cadherin production, and inhibits in vitro invasion of tumor cells

Role of angiotensin II receptor blockers in atherosclerotic plaque stability.

Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease

Is hypertension an inflammatory process?

The biochemical, biological, and pathological kaleidoscope of cell surface substrates processed by matrix metalloproteinases.

Matrix metalloproteinases: useful and deleterious.

ACE inhibitors to block MMP-9 activity: new functions for old inhibitors.

Proteinase activity and receptor cleavage: mechanism for insulin resistance in the spontaneously hypertensive rat.

Plasma levels of active extracellular matrix metalloproteinases 2 and 9 in patients with essential hypertension before and after antihypertensive treatment.

The effect of Ca2+ channel antagonists on plasma concentrations of matrix metalloproteinase-2 and -9 in essential hypertension.

P304

521-533

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/10641960802668730

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P577

2009-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

38064871

http://www.w3.org/2001/XMLSchema#string

P698

19886850

http://www.w3.org/2001/XMLSchema#string

P932

2875383

http://www.w3.org/2001/XMLSchema#string